RETREG2

Across TCGA pan-cancer cohorts, RETREG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RETREG2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RETREG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RETREG2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where RETREG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.212	0.972	.010	6	view →
GBM	OS	Tertile	All	0.645	0.397	.006	6	view →
HNSC	OS	Quartile	All	0.819	0.611	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RETREG2–CCRCC (DFS)

Open the CCRCC breakdown →